A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma

Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Study ID
NCT06618664
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Hepatocellular Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • SHR-8068 — DRUG
    SHR-8068: injection, 50 mg/10 mL, intravenous infusion
  • Adebrelimab — DRUG
    Adebrelimab: injection, 600 mg/12 mL, intravenous infusion
  • Bevacizumab — DRUG
    Bevacizumab: injection, 100 mg/4 mL, intravenous infusion
  • Sintilimab — DRUG
    Sintilimab: injection, 100 mg/10 mL, intravenous infusion
  • Atezolizumab injection — DRUG
    Atezolizumab injection.

Study Details

THis study aims to evaluate the efficacy of SHR-8068 combined with Adebrelimab and Bevacizumab compared with Sintilimab or Atezolizumab combined with Bevacizumab for the first-line treatment of advanced HCC.

Key Dates

Start date
Oct 28, 2024
Status verified
Apr 2026
Primary completion
Sep 30, 2026
Completion
Dec 31, 2030

Study Design

Enrollment
590 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SHR-8068 combined with Adebrelimab and Bevacizumab
  • Active Comparator: Sintilimab combined with Bevacizumab or Atezolizumab

Primary Outcome Measure

Progression Free Survival (PFS) [ Time Frame: From Randomization to the first occurrence of disease progression as determined by the Blinded Independent Review Committee (BIRC) according to RECIST v1.1 or initiation of new anti-tumor therapy (up to approximately 36 months) ]

Central Contacts

Related Studies